Received Dec 26, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | UNK | — |
Guillian-Barre Syndrome; This serious case was reported by a consumer via interactive digital media and described the occurrence of guillain barre syndrome in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis. On an unknown date, the patient received Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced guillain barre syndrome (Verbatim: Guillian-Barre Syndrome) (serious criteria GSK medically significant). The outcome of the guillain barre syndrome was not reported. It was unknown if the reporter considered the guillain barre syndrome to be related to Shingles vaccine. The company considered the guillain barre syndrome to be unrelated to Shingles vaccine. Additional Information: GSK Receipt Date: 21-DEC-2025 This case was reported by a patient via interactive digital media. Patient got his/her shingles shot and then became paralyzed. Patient experienced loss of muscles, extreme weakness, pain, neuropathy, and many other complications for the rest of his/her life. People hear about the 3 percent who develop Guillain-Barre Syndrome (GBS), and patient was one of the unlucky 3 percent. Patient had no options, no vaccine injury claim allowed, and no disability support just a new life to adjust to. It was devastating. The batch number was not provided, and we are unable to contact the reporter.; Sender's Comments: A case of Guillain-Barre syndrome (BCWG Level 3), an unknown time after receiving Shingles vaccine, in a patient. Causal association is indeterminate. Based on the available information a possible causality that the event was caused by the GSK product cannot be ascertained. Consent for further follow-up has not been received.